Amanote Research
Register
Sign In
Alpelisib Extends PFS in PIK3CA-Mutant Breast Cancer
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-nb2018-146
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
November 9, 2018
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Correction To: Unexpected Benefit From Alpelisib and Fulvestrant in a Woman With Highly Pre-Treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer
Clinical Drug Investigation
Medicine
Pharmacology
mTORC1 Inhibition Is Required for Sensitivity to PI3K P110 Inhibitors in PIK3CA-Mutant Breast Cancer
Science Translational Medicine
Medicine
PIK3CA Mutation Predicts Resistance to Breast Cancer Therapy
Cancer Discovery
Oncology
Specific Apoptosis Induction by the Dual PI3K/mTor Inhibitor NVP-BEZ235 in HER2 Amplified and PIK3CA Mutant Breast Cancer Cells
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Mutant PIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in an Orthotopic Model
Cancer Research
Cancer Research
Oncology
Novel Mutant-Enriched Sequencing Identified High Frequency of PIK3CA Mutations in Pharyngeal Cancer
International Journal of Cancer
Cancer Research
Oncology
PIK3CA Somatic Mutations in Breast Cancer: Mechanistic Insights From Langevin Dynamics Simulations
Proteins: Structure, Function and Genetics
Biochemistry
Structural Biology
Molecular Biology
Mutational Hotspot in Exon 20 of PIK3CA in Breast Cancer Among Singapore Chinese
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
Combination PI3K/MEK Inhibition Promotes Tumor Apoptosis and Regression in PIK3CA Wild-Type, KRAS Mutant Colorectal Cancer
Cancer Letters
Cancer Research
Oncology
